Equity Overview
Price & Market Data
Price: $7.00
Daily Change: +$0.33 / 4.71%
Daily Range: $6.99 - $7.00
Market Cap: $164,860,208
Daily Volume: 825
Performance Metrics
1 Week: 22.39%
1 Month: 16.20%
3 Months: 59.95%
6 Months: 126.1%
1 Year: 101.5%
YTD: 55.48%
Company Details
Employees: 104
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.